首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.
【24h】

In vivo characterization of muscarinic receptors in peripheral tissues: evaluation of bladder selectivity of anticholinergic agents to treat overactive bladder.

机译:外周组织中毒蕈碱受体的体内特征:抗胆碱能药物治疗膀胱过度活动症的膀胱选择性评估。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The present study was undertaken to characterize in vivo muscarinic receptors in peripheral tissues (urinary bladder, submaxillary gland, colon, stomach, heart) of mice, and further to evaluate bladder-selectivity of anticholinergic agents to treat overactive bladder. Following i.v. injection of [(3)H]QNB in mice, the radioactivity in peripheral tissues was exclusively detected as the unchanged form. The in vivo specific [(3)H]QNB binding in particulate fraction of tissue homogenates of mice showed a pharmacological specificity which characterized muscarinic receptors. Binding parameters (K (d) and B (max)) for in vivo specific [(3)H]QNB binding differed between mouse tissues. Oral administration of oxybutynin attenuated significantly in vivo specific [(3)H]QNB binding in all tissues of mice. From ratios of AUC(urinary bladder)/AUC(other tissues) of time-dependent muscarinic receptor occupancy, oral oxybutynin has been shown to exert little urinary bladder selectivity. Following oral administration of propiverine, there was a significant reduction of in vivo specific [(3)H]QNB binding in the urinary bladder, colon and submaxillary gland, but not in the stomach and heart. From the ratios of AUC(urinary bladder) to AUC(submaxillary gland) or AUC (heart), it has been shown that oral propiverine exerts higher selectivity to muscarinic receptors in the urinary bladder than in the submaxillary gland and heart. Similarly, tolterodine displayed high selectivity to muscarinic receptors in the urinary bladder than in the submaxillary gland. Thus, the present study has demonstrated that [(3)H]QNB may be a useful ligand for in vivo characterization of muscarinic receptor binding of anticholinergic agents to treat overactive bladder. Propiverine and tolterodine have exhibited in vivo selectivity of muscarinic receptor in the mouse urinary bladder rather than in the submaxillary gland, and such receptor binding specificity may be the reason of lower incidence of dry mouth.
机译:进行本研究以表征小鼠外周组织(膀胱,上颌下腺,结肠,胃,心脏)中的体内毒蕈碱受体,并进一步评估抗胆碱能药对膀胱过度活动症的膀胱选择性。继i.v.在小鼠体内注射[(3)H] QNB后,仅检测到周围组织中的放射性没有改变。小鼠组织匀浆的颗粒级分中的体内特异性[(3)H] QNB结合表现出毒蕈碱受体特征的药理学特异性。体内特异性[(3)H] QNB结合的结合参数(K(d)和B(max))在小鼠组织之间有所不同。奥昔布宁的口服给药显着减弱了小鼠所有组织中的体内特异性[(3)H] QNB结合。从时间依赖性毒蕈碱受体占有率的AUC(膀胱)/ AUC(其他组织)的比率来看,口服奥昔布宁已显示出对膀胱的选择性很小。口服丙泊明后,在膀胱,结肠和上颌下腺中,但在胃和心脏中,体内特异性[(3)H] QNB结合明显减少。从AUC(膀胱)与AUC(上颌下腺)或AUC(心脏)的比率,已经显示,口服丙泊明比在上颌下腺和心脏中对膀胱中的毒蕈碱受体具有更高的选择性。同样,托特罗定对膀胱中毒蕈碱受体的选择性高于对下颌下腺。因此,本研究表明[(3)H] QNB可能是体内表征抗胆碱能药物的毒蕈碱受体结合以治疗膀胱过度活动症的有用配体。异丙肾上腺素和托特罗定在小鼠膀胱中而不是在颌下腺中具有毒蕈碱受体的体内选择性,并且这种受体结合特异性可能是口干发生率较低的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号